{'fraction_non_alphanumeric': 0.041922290388548056, 'fraction_numerical': 0.02147239263803681, 'mean_word_length': 5.751724137931035, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
TUMOUR‐PROMOTING COMPOUND (TPA) ENHANCES INTERFERON PRODUCTION IN CHRONIC LYMPHATIC LEUKAEMIA CELLS

In chronic lymphatic leukaemia (CLL), accumulation of long-lived, abnormal lymphocytes characteristically is accompanied by an impairment of both cellular and humoral immunoreactivity. Among other defects in lymphocyte function, reduced production of interferon in response to viral inducers and mitogenic stimuli has been observed in patients with CLL (Lee et a!, 1966; Epstein & Cline, 1974). We recently noticed that pretreatment of cells of a Burkitt's lymphoma-derived cell line with n-butyric acid, glucocorticoid hormones or the tumour-promoting phorbol ester, 12-0-tetradecanoylphorbol-13-acetate (TPA), resulted in a markedly enhanced virus-induced interferon production (Adolf & Swetly, 1979a, b, 1980). We have now studied the effects of these substances on virus-induced interferon synthesis in leucocytes from patients with CLL as well as from healthy individuals.